Physician profile
Benjamin Citrin
NPI 1750461620
$11,251.13
in general payments reported to CMS, 2019-2025
28 companies · $1,201 in 2025
The $1,201 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,638 · 2020: $1,018 · 2021: $1,554 · 2022: $1,238 · 2023: $1,264 · 2024: $1,338 · 2025: $1,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,803.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $2,413.23 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $1,185.17 | 2019-2025 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $1,057.49 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $879.76 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $690.41 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $671.45 | 2019-2025 | Jardiance |
| Pfizer INC. | $648.90 | 2019-2025 | |
| Medtronic, INC. | $585.74 | 2021-2025 | Venaseal, Closurefast |
| Scpharmaceuticals INC. | $476.32 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $445.11 | 2019-2024 | Lifevest |
| Amarin Pharma, INC. | $443.33 | 2019-2023 | |
| Novo Nordisk INC | $410.90 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $343.70 | 2021-2025 | Verquvo |
| Boston Scientific Corporation | $222.97 | 2019-2025 | Varithena Administration Pack |
| Esperion Therapeutics, INC. | $143.93 | 2020-2025 | Nexletol |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $114.45 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $108.03 | 2024 | |
| Kiniksa Pharmaceuticals, Ltd. | $67.51 | 2022-2023 | Arcalyst |
| Inspire Medical Systems, INC. | $66.13 | 2024 | Inspire |
| Bard Peripheral Vascular, INC. | $53.25 | 2021-2024 | Venclose Maven Catheter |
| Gilead Sciences, INC. | $50.36 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.20 | 2025 | |
| Vifor Pharma, INC. | $35.38 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $30.80 | 2025 | Evkeeza |
| Kiniksa Pharmaceuticals International, Plc | $21.15 | 2024 | Arcalyst |
| Daiichi Sankyo INC. | $13.87 | 2024 | Injectafer |
| Angiodynamics, INC. | $13.80 | 2021 | |
| Lilly USA, LLC | $13.79 | 2024 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Citrin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.